However, IFN reduced the risk of HCC in HCV-related liver cirrhosis [97] whereas the HALT-C study showed that long-term therapy with IFN did not reduce the rate of disease progression in patients with chronic hepatitis C and advanced fibrosis, with or without cirrhosis [98]. This evidence concerns the gene IFNA1 and chronic hepatitis C virus infection.